Botulinum toxin: Bioweapon & magic drug

Indian Journal of Medical Research

Volumn 132, Issue 11, 2010, Pages 489-503

  Dhaked, Ram Kumar ^a   Singh, Manglesh Kumar ^a   Singh, Padma ^a   Gupta, Pallavi ^a  

^a DEFENCE RESEARCH AND DEVELOPMENT ESTABLISHMENT   (India)

Author keywords

Botulinum toxin; Botulism; Clostridium botulinum; Neurotoxin; Proteinase

Indexed keywords

ANTIBIOTIC AGENT; BABYBIG; BOTULINUM ANTISERUM; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; BOTULINUM TOXOID; DNA VACCINE; MYOBLOCK; NEUROBLOCK; PENICILLIN DERIVATIVE; RECOMBINANT VACCINE; TOXOID; UNCLASSIFIED DRUG;

ANTIBIOTIC THERAPY; ANUS FISSURE; ASSAY; BACKACHE; BACTERIUM ISOLATION; BIOLOGICAL WARFARE; BIOLOGICAL WARFARE AGENT; BIOSENSOR; BLEPHAROSPASM; BOTULISM; BRUXISM; CANADA; CANCER THERAPY; CLOSTRIDIA DIRECTED ENZYME PRO DRUG THERAPY; CLOSTRIDIUM BOTULINUM; DEBRIDEMENT; DETRUSOR DYSSYNERGIA; DISEASE TRANSMISSION; DRUG APPROVAL; DYSTONIA; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGUS ACHALASIA; FACE; FOOD AND DRUG ADMINISTRATION; FOOD CONTAMINATION; HUMAN; HYPERHIDROSIS; IMMUNOASSAY; INDIA; MASS SPECTROMETRY; MIGRAINE; MILITARY MEDICINE; MOTOR DYSFUNCTION; MUSCLE SPASM; NEUROLOGIC DISEASE; NEUROMUSCULAR BLOCKING; NEUROMUSCULAR DISEASE; NEUROTOXICITY; NONHUMAN; PAIN; POLYMERASE CHAIN REACTION; PROSTATITIS; PULSED FIELD GEL ELECTROPHORESIS; REJUVENATION; REVIEW; SOLID TUMOR; SPASTICITY; STRABISMUS; TIC; TOXIN ANALYSIS; TREMOR; UNITED STATES; VACCINATION; VAGINISM; WATER CONTAMINATION; WOUND CARE; WOUND INFECTION; WRINKLE; CHEMISTRY; DRUG ANTAGONISM; DYSKINESIA; GENETICS; PATHOPHYSIOLOGY;

BIOLOGICAL WARFARE AGENTS; BOTULINUM TOXINS; BOTULISM; CLOSTRIDIUM BOTULINUM; DYSKINESIAS; HUMANS; SPASM; STRABISMUS;

EID: 78649466897     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Review

References (184)

1. Bigalke H, Shoer LF. In: Aktories K, Just I, editors. Clostridial neurotoxins: Handbook of experimental pharmacology. Berlin: Springer Verlag: 2001. p. 407-47.
2. Hatheway CL. Clostridium botulinum and other Clostridia that produce botulinum neurotoxins. In: Hauschild AHW, Dodds KL, editors. Clostridium botulinum: Ecology and control in foods. New York: Marcel Dekkar; 1992. p. 3-20.
3. Lamanna C. The most poisonous poison. Science 1959; 130: 763-72.
4. Dolman CE. Botulism as a world health problem. In: Lewis KH, Kassel Jr. K, editors. Botulism. Cincinnati: Ohio: U. S. Department of Health, Education, and Welfare. Public Health Service; 1964. p. 5-32.
5. Van Ermengem, E. About a new anaerobic bacillus and its relationship to botulism. Z Hyg Infektionskr 1897; 26: 1-56.
6. Bengston IA. Studies on organisms concerned as causative factors in botulism. Hyg Lab Bull 1924; 136: 101.
7. Midura TF. Update: infant botulism. Clin Microbiol Rev 1996; 9: 119-25.
8. Hughes JM, Blumenthal JR, Merson MH, Lombard GL, Dowell VR Jr., Gangarosa EJ. Clinical features of type A and B food-borne botulism. Ann Intern Med 1981; 95: 442-5.
9. Hatheway CL. Botulism: the present status of the disease. Curr Top Microbiol Immunol 1995; 195: 55-75.
10. Hatheway CL. Botulism. In: Balows A, Hausler WH, Ohashi M, Turnano A, editors. Laboratory diagnosis of infectious diseases: principles and practice, vol. 1. New York: Berlin Heidelberg, Springer; 1988. p. 111-33.
11. Hauschild AHW. Epidemiology of human foodborne botulism. In: Hauschild AHW, Dodds KL, editors. Clostridium botulinum. Ecology and Control in foods. New York: Marcel Dekker; 1992. p. 68-104.
12. Angulo FJ, Getz J, Taylor JP, Hendricks KA, Hatheway CL, Barth SS, et al. A large outbreak of botulism: the hazardous baked potato. J Infect Dis 1998; 178: 172-7.
13. Centers for Diseases Control (CDC). Botulism associated with canned chili sauce. Atlanta: CDC; 2007 July-Aug.
14. Chou JH, Hwant PH, Malison MD. An outbreak of type A foodborne botulism in Taiwan due to commercially preserved peanuts. Int J Epidemiol 1988; 17: 899-902.
15. Kalluri P, Crowe C, Reller M, Gaul L, Hayslett J, Barth S, et al. An outbreak of foodborne botulism associated with food sold at a salvage store in Texas. Clin Infect Dis 2003; 37: 1490-5.
16. O'Mahony M, Mitchell E, Gilbert RJ, Hutchinson DN, Begg NT, Rodhouse JC, et al. An outbreak of foodborne botulism associated with contaminated hazelnut yoghurt. Epidemiol Infect 1990; 104: 389-95.
17. St Louis ME, Peck SH, Bowering GB, Bltherwick J, Banerjee S, Kettyls GD, et al. Botulism from chopped garlic: delayed recognition of a major outbreak. Ann Intern Med 1988; 108: 363-8.
18. Steth AN, Wiersma P, Atrubin D, Dubey V, Zink D, Skinner G, et al. International outbreak of severe botulism with prolonged toxemia caused by commercial carrot juice. Clin Infect Dis 2008; 47: 1245-51.
19. Villar RG, Shapiro RL, Busto S, Riva-Posse C, Verdejo G, Farace MI, et al. Outbreak of type A botulism and development of a botulism surveillance and antitoxin release system in Argentina. JAMA 1999; 281: 1334-8.
20. Midura TF, Arnon SS. Infant botulism: Identification of Clostridium botulinum and its toxin in feces. Lancet 1976; 2: 934-6.
21. Shapiro RL, Hatheway CL, Swerdlow DL. Botulism in the United States:A clinical and epidemiological review. Ann Intern Med 1998; 129: 221-8.
22. Arnon SS. Human tetanus and human botulism. In: Rood JI, McClane BA, Songer JG, Titball RW, editors. The Clostridia: Molecular biology and pathogenesis. London: Academic press; 1997. p. 95-115.
23. Arnon SS, Midura TF, Damus K. Honey and other environmental risk factors for infant botulism. J Pediatr 1979; 194: 331-6.
24. Nevas M, Lindstrom M, Virtanen A, Hielm S, Kuusi M, Arnon SS, et al. Infant botulism acquired from household dust presenting as sudden infant death syndrome. J Clin Microbiol 2005; 43: 511-3.
25. Koepke R, Sobel J, Arnon SS. Global occurrence of infant botulism, 1976-2006. Paediatrics 2008; 122: 73-82.
26. Passaro DJ, Werner SB, McGee J, MacKenzie WR, Vugia DJ. Wound botulism associated with black tar heroin among injecting drug user. JAMA 1998; 279: 859-63.
27. Brett MM, Hood J, Brazier JS, Duerden BI, Hahne SJ. Soft tissue infections caused by spore-forming bacteria in injecting drug users in the United Kingdom. Epidemiol Infect 2005; 133: 575-82.
28. Preuss SF, Veelken F, Galldiks N, Klussmann JP, Neugebauer P, Nolden-Hoverath S, et al. A rare differential diagnosis in dysphagia: wound botulism. Laryngoscope 2006; 116: 831-2.
29. Artin I, Bjorkman P, Cronqvist J, Radstrom P, Holst E. First case of type E wound botulism diagnosed using real-time PCR. J Clin Microbiol 2007; 45: 3589-94.
30. Critchley JMR. A comparison of human and animal botulism: A review. J R Soc Med 1991; 84: 295-8.
31. Smith LDS, Sugiyama H. Botulism: The organism, its toxins, the disease, 2nd ed. Springfield, Illinois: Charles C Thomas; 1988. p. 171.
32. Dutra IS, Seifert HSH. Water holes- incubation areas for botulism in Brazil? In: Bohnel H, editor. Proceeding of the 1st International conferrence on identification and immunbiology of Clostridia: Diagnosis and prevention of clostridioses. Teistungen: Germany; 1998.
33. Eklund MW. Control in fishery products. In: Hauschild AHW, Dodds KL, editors. Clostridium botulinum. Ecology and control in foods. New York: Marcel Dekker; 1992. p. 209-32.
34. Myllykoski J, Lindstrom M, Keto-Timonen R, Soderholm H, Jakala J, Kallio H, et al. Type C bovine botulism outbreak due to carcass contaminated non-acidified silage. Epidemiol Infect 2008; 7: 1-10.
35. Holzer E. Botulism caused by inhalation. Med Klin 1962; 41: 1735-40.
36. Franz DR, Pitt LM, Clayton MA, Hanes MA, Rose KJ. Efficacy of prophylactic and therapeutic administration of antitoxin for inhalation botulism. In: DasGupta BR, editior. Botulinum and tetanus Neurotoxins and Biomedical aspects. New York: Plenum Press; 1993. p. 473-6.
37. Park JB, Simpson LL. Inhalational poisoning by botulinum toxin and inhalational vaccination with its heavy chain component. Infect Immun 2003; 71: 1147-54.
38. Sobel J. Botulism. Clin Infect Dis 2005; 4: 1167-73.
39. Chertow DS, Tan ET, Maslanka SE, Schulte J, Bresnitz EA, Weisman RS, et al. Botulism in 4 adults following cosmetic injections with an unlicensed highly concentrated botulinum preparation. JAMA 2006; 296: 2476-9.
40. Chaudhry R, Dhawan B, Kumar D, Bhatia R, Gandhi JC, Patel RK, et al. Outbreak of suspected Clostridium butyricum botulism in India. Emerg Infect Dis 1998; 4: 506-7.
41. Agarwal AK, Goel A, Kohli A, Rohtagi A, Kumar R. Food- borne botulism. J Assoc Physicians India 2004; 52: 677-8.
42. Dhaked RK, Sharma SK, Parida MM, Singh L. Isolation and characterization of Clostridium botulinum Type 'E' from soil of Gwalior, India. J Nat Toxins 2002; 11: 49-56.
43. Lalitha KV, Gopakumar K. Distribution and ecology of Clostridium botulinum in fish and aquatic environments of a tropical region. Food Microbiol 2000; 17: 535-41.
44. Lalitha KV, Surendran PK. Occurrence of Clostridium botulinum in fresh and cured fish in retail trade in Cochin (India). Int J Food Microbiol 2002; 72: 169-74.
45. Joshy L, Chaudhry R, Chandel DS. Multiplex PCR for the detection of Clostridium. botulinum & C. perfringens toxin genes. Indian J Med Res 2008; 128: 206-8.
46. Leuchs J. Contributions to the knowledge of the toxin and antitoxin of Bacilius botulinus. Ztschr Hyg Infektskh 1910; 65: 55-84.
47. Burke GS, Notes on Bacillus botulinus. J Bacteriol 1919; 4: 555-65.
48. Seddon HR. Bulbar paralysis in cattle due to the action of toxicogenic bacillus, with a discussion on the relationship of the condition to forage poisoning (botulism). J Comp Pathol Therap 1922; 35: 147-90.
49. Thieler A, Viljoen PR, Green HH, du Toit PJ, Meier H, Robinson EM. Lamsiekte (parabotulism) in cattle in South Africa. 11th and 12th Report of Director Veterinary Education and Research Part II, Sect. 5 Department of Agriculture, Union South Africa; 1927. p. 1201-11.
50. Gunnison JB, Cummings JR, Meyer KF. Clostridium botulinum type E. Proc Soc Exp Biol Med 1953; 35: 278-80.
51. Moller V, Scheibel I. Preliminary report on the isolation of an apparently new type of Clostridium botulinum. Acta Pathol Microbiol Scand 1960; 48: 80.
52. Gimenez DF, Ciccarelli AS. Another type of Clostridium botulinum. Zentralbl Bakteriol Prasiten kd Infektionskr Hyg Abt 1 Orig 1970; A215: 221-4.
53. Lee WH, Reimann H. The genetic relatedness of proteolytic Clostridium botulinum strains. J Gen Microbiol 1970; 64: 85-90.
54. Holdeman LV, Brooks JB. Variations among strains of Clostridium botulinum and related clostridia. In: Herzberg M, editor. Proceedings of the First US-Japan conference on toxigenic microorganisms. Washingtan: US Government Printing Office; 1970. p. 278-86.
55. Hutson RA, Thompson DE, Lawson PA, Schocken-Itturino RP, Bottger EC, Collins MD. Genetic interrelationships of proteolytic Clostridium botulinum types A, B, and F and other members of Clostridium botulinum complex as revealed by small-subunit rRNA gene sequences. Antonie van Leeuwenhoek 1993; 64: 273-83.
56. Hutson RA, Thompson DE, Collins MD. Genetic interrelationships of saccharolytic Clostridium botulinum types B, E and F and related clostridia as revealed by small-subunit rRNA gene sequences. FEMS Microbiol Lett 1993; 108: 103-10.
57. Collins MD, Lawson PA, Willems A, Cordoba JJ, Fernandez- Garayzabal J, Garcia P, et al. The phylogeny of the genus Clostridium: proposal of five new genera and eleven new species combinations. Int J Syst Bacteriol 1994; 44: 812-26.
58. Smith LDS, Hobbs G. Genus III. Clostridium prazmowski 1980, 23. In: Buchanen RE, Gibson NE, editors. Bergey's mannual of determinative bacteriology, 8th ed. Baltimore: Williams & Wilkins; 1974. p. 551-72.
59. Suen JG, Hatheway CL, Steigerwalt AG, Brenner DJ. Clostridium botulinum sp. nov: A genetically homogenous group composed of all strains of Clostridium botulinum toxin type G and some non-toxigenic strains previously identified as Clostridium subterminale or Clostridium hastiforme. Int J Syst Bacteriol 1988; 38: 375-81.
60. Aureli P, Fenicia L, Pasolini B, Gianfranceschi M, McCroskey LM, Hatheway CL. Two cases of type E infant botulism in Rome caused by neurotoxigenic Clostridium butyricum. J Infect Dis 1986; 154: 207-11.
61. Hall JD, McCroskey LM, Pinkomb BJ, Hatheway CL. Isolation of an organism resembling Clostridium beratii which produce type F botulinal toxin from an infant with botulism. J Clin Microbiol 1985; 21: 654-5.
62. Minton NP. Molecular genetics clostridial neurotoxins. Curr Top Microbiol Immunol 1995; 95: 161-95.
63. Brinkac LM, Daugherty S, Dodson RJ, Madupu R, Brown JL, Bruce D, et al. Complete sequence of Clostridium botulinum strain Langeland/NCTC10281/Type F Submitted to the EMBL/GenBank/DDBJ databases. 2007 JUN.
64. Brinkac LM, Brown JL, Bruce D, Detter C, Munk C, Smith LA, et al. Complete sequence of Clostridium botulinum strain type B Eklund. Submitted to the EMBL/GenBank/DDBJ databases. 2008 APR.
65. Sebaihia M, Peck MW, Minton NP, Thomson NR, Holden MTG, Mitchell WJ, et al. Genome sequence of a proteolytic (Group I) Clostridium botulinum strain Hall A and comparative analysis of the clostridial genomes. Genome Res 2007; 17: 1082-92.
66. Smith TJ, Hill KK, Foley BT, Detter JC, Munk AC, Bruce DC, et al. Analysis of the neurotoxin complex genes in Clostridium botulinum A1-A4 and B1 strains: BoNT/A3, /Ba4 and /B1 clusters are located within plasmids. PLoS ONE. 2007; 2: E1271-E1271.
67. Shrivastava S, Brinkac LM, Brown JL, Bruce D, Detter CC, Johnson EA, et al. Genome sequence of Clostridium botulinum A2 Kyoto. Submitted to the EMBL/GenBank/DDBJ databases. 2008 OCT.
68. Shrivastava S, Brown JL, Bruce D, Detter C, Munk C, Smith LA, et al. Genome sequence of Clostridium botulinum Ba4 strain 657. Submitted to the EMBL/GenBank/DDBJ databases. 2008 MAY.
69. Peck MW. Clostridium botulinum and the safety of minimally heated, chilled foods: an emerging issue? J Appl Micrbiol 2006; 101: 556-70.
70. Schiavo G, Rossetto O, Tonello F, Montecucco C. Intracellular target and metalloprotease activity of tetanus and botulinum neurotoxins. Curr Top Microbiol Immunol 1995; 195: 257-74.
71. Villar RG, Elliot SP, Davenport KM. Botulism: the many faces of botulinum toxin and its potential for bioterrorism. Infect Dis Clin N Am 2006; 20: 313-27.
72. Sugii S, Sakaguchi G. Molecular construction of Clostridium botulinum type A toxins. Infect Immun 1975; 12: 1262-70.
73. Inoue K, Fuginaga Y, Watanabe T, Oshyama T, Takeshi K, Moriishi K, et al. Molecular composition of Clostridium botulinum type A progenitor toxins. Infect Immun 1996; 64: 1589-94.
74. Chen F, Kuziemco GM, Stevens R. Biophysical characterization of the stability of the 150-Kilodalton botulinum toxin, the non-toxic component and the 900-Kilodalton botulinum toxin complex species. Infect Immun 1998; 66: 2420-5.
75. Sakaguchi G, Kozaki S, Ohnishi I. Structure and function of botulinum toxins. In: Alouf JE, Fehrenbach FJ, Freer JH, Jeljaszewics J, editors. Bacterial protein toxins. London: Academic Press; 1984. p. 435-43.
76. Montecucco C, Schiavo G. Mechanism of action of tetanus and botulinum neurotoxins. Mol Microbiol 1994; 13: 1-8.
77. Schiavo G, Malizio C, Trimble WS, Polverino de Laureto P, Milan G, et al. Botulinum G neurotoxin cleaves VAMP/synaptobrevin at a single Ala-Ala peptide bond. J Biol Chem 1994; 269: 20213-6.
78. Binz T, Blasi J, Yamasaki S, Baumeister A, Link E, Sudhof TC, et al. Proteolysis of SNAP-25 by type E and A botulinum nerotoxins. J Biol Chem 1994; 269: 1717-20.
79. Schiavo G, Rossetto O, Catsicas S, Polverino de Laureto P, DasGupta BR, et al. Identification of the nerve terminal targets of botulinum neurotoxin serotypes A, D, and E. J Biol Chem 1993; 268: 23784-7.
80. Schiavo G, Santucci A, DasGupta BR, Mehta PP, Jontes J, Benfenati F, et al. Botulinum neurotoxin serotypes A and E cleave SNAP-25 at distinct COOH-terminal peptide bonds. FEBS Lett 1993; 335: 99-103.
81. Osen-Sand A, Staple JK, Naldi E, Schiavo G, Rossetto O, Petitpierre S, et al. Common and distinct fusion proteins in axonal growth and transmitter release. J Comp Neurol 1996; 367: 222-34.
82. Schiavo G, Benfenati F, Poulain B, Rossetto O, Polverino de Laureto P, DasGupta BR, et al. Tetanus and botulism B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 1992; 359: 832-5.
83. Schiavo G, Shone CC, Rossetto O, Alexander FC, Montecucco C. Botulinum neurotoxin serotype F is a zinc endopeptidase specific for VAMP/synaptobrevin. J Biol Chem 1993; 268: 11516-9.
84. Yamazaki S, Baumeister A, Binz T, Blasi J, Link E, Cornille F, et al. Cleavage of members of synaptobrevin/VAMP family by types D and F botulinal neurotoxins and tetanus toxin. J Biol Chem 1994; 269: 12764-72.
85. Blasi J, Chapman ER, Yamasaki S, Binz T, Niemann H, Jahn R. Botulinum neurotoxin C1 block the release by means of cleavage HPC-1/syntaxin. EMBO J 1993; 12: 4821-8.
86. Schiavo G, Shone CC, Bennett MK, Scheller RH, Montecucco C. Botulinum neurotoxin type C cleaves a single Lys-Ala bond within the carboxyl-terminal region of syntaxins. J Biol Chem 1995; 270: 10566-70.
87. Lilly T, Harmon SM, Kautter DA, Solomon HM, Lynt RK. An improved medium for detection of Clostridium botulinum type E. J Milk Food Technol 1971; 34: 492-7.
88. Kautter DA, Solomon HM, Lake DE, Bernard DT, Mills DC. Clostridium botulinum and its toxin. In: Vanderzant C, Splittstoesser DF, editors. Compendium of methods for microbiological examination of foods, 3rd ed. Washington: American Public Health Association; 1992. p. 605-21.
89. Dezfulian M, McCroskey LM, Hatheway CL, Dowell VR Jr. Selective medium for isolation of Clostridium botulinum from human feces. J Clin Microbiol 1981; 13: 526-31.
90. Hobbs G. Clostridium botulinum and its importance in fishery products. In: Chechester CO, Mrak EM Stewart GF, editors. Advances in food research. New York: Academic Press Inc. 1976. p. 135-85.
91. Varnam AH, Evans MG. Clostridium botulinum. In: Food-borne pathogens- an illustrated text. London: Wolfe Publishing; 1991. p. 289-311.
92. Cato EP, George WL, Finegold SM. Genus Clostridium. In: Sneath PHA, Mair NS, Sharpe ME, Hold JG, editors. Bergey's 1986. manual of systematic bacteriology, vol. 2, Baltimore, MA: Williams and Wilkins; p. 1141-200.
93. Smoot LA, Pierson MD. Effect of oxidation-reduction potential on the outgrowth and chemical inhibition of Clostridium botulinum 10755A spores. J Food Sci 1979; 44: 700-4.
94. Huss HH, Schaeffer I, Pedersen A, Jepsen A. Toxin production by Clostridium botulinum type E in smoked fish in relation to the measured oxidation reduction potential (Eh), packaging method, and associated microflora. Adv Fish Sci Technol 1980; 13: 476-9.
95. Code for Federal Regulations (CFR). Thermally processed low-acid foods packaged in hermetically sealed containers: definitions. Title 21. Section 113. 3. US Govt. Print Office Washington, DC. 1981.
96. Denny JB, Goeke DJ Jr. Sternberg R. Inoculation of Clostridium botulinum in canned bread with special reference to water activity. National Canners Association. Washington DC. 1969; Res Rep No. 4-69.
97. Emodi AS, Lechowich RV. Low temperature growth of type E Clostridium botulinum spores. 2. Effects of solutes and incubation temperature. J Food Sci 1969; 34: 82-93.
98. Peruski AH, Johnson LH, Peruski LF. Rapid and sensitive detection of biological warfare agents using time-resolved fluorescence assays. J Immunol Meth 2002; 263: 35-41.
99. Dong M, Tepp WH, Johnson EA, Chapman ER. Using fluorescent sensors to detect botulinum neurotoxin activity in vitro and in living cells. Proc Natl Acad Sci USA 2004; 101: 14701-6.
100. Sharma SK, Ferreira JL, Eblen BS, Whiting RC. Detection of type A, B, E, and F Clostridium botulinum neurotoxins in foods by using an amplified enzyme-linked immunosorbent assay with digoxigenin-labeled antibodies. Appl Environ Microbiol 2006; 72: 1231-8.
101. Liu W, Montana V, Chapman, ER, Mohideen U, Parpura V. Botulinum toxin type B micromechanosensor. Proc Natl Acad Sci USA 2003; 100: 13621-5.
102. Barr JR, Moura H, Boyer AE, Woolfitt AR, Kalb SR, Pavlopoulos A, et al. Botulinum neurotoxin detection and differentiation by mass spectrometry. Emerg Infect Dis 2005; 11: 1578-83.
103. Bagramyan K, Barash JR, Arnon SS, Kalkum M. Attomolar detection of botulinum toxin type A in complex biological matrices. PLoS ONE 2008; 3(4): e2041.
104. Chao HY, Wang YC, Tang SS, Liu HW. A highly sensitive immuno-polymerase chain reaction assay for Clostridium botulinum neurotoxin type A. Toxicon 2004; 43: 27-34.
105. Mason JT, Xu L, Sheng ZM, O'Leary TJ. A liposome-PCR assay for the ultrasensitive detection of biological toxins. Nat Biotechnol 2006; 24: 555-7.
106. Varnum SM, Warner MG, Dockendorff B, Anheier Jr. NC, Lou J, Marks JD, et al. Enzyme-amplified protein microarray and a fluidic renewable surface fluorescence immunoassay for botulinum neurotoxin detection using high affinity recombinant antibodies. Analytica Chimica Acta 2006; 570: 137-43.
107. Ferracci G, Miquelis R, Kozaki S, Seagar M, Leveque C. Synaptic vesicle chips to assay botulinum neurotoxins. J Biochem 2005; 391: 659-66.
108. Ahn-Yoon S, DeCory TR, Durst RA. Ganglioside-liposome immunoassay for the detection of botulinum toxin. Anal Bioanal Chem 2004; 378: 68-75.
109. Wictome M, Shone CC. Botulinum neurotoxins: Mode of action and detection. J Appl Microbiol 1998; 84: S87-97.
110. Cherington M. Clinical spectrum of botulism. Muscle Nerve 1998; 21: 701-10.
111. Glasby C, Hatheway CL. Fluorescent-antibody reagents for the identification of Clostridium botulinum. J Clin Microbiol 1983; 18: 1378-83.
112. Lilly T, Kautter DA, Lynt RK, Solomon HM. Immunodiffusion detection of Clostridium botulinum colonies. J Food Prot 1984; 47: 868-75.
113. Ogert RA, Brown JE, Singh BR, Shriver-Lake LC, Ligler FS. Detection of Clostridium botulinum toxin A using a fiber optic-based biosensor. Anal Biochem 1992; 205: 306-12.
114. Ekong TAN, McLellan K, Sesardic D. Immunological detection of Clostridium botulinum type A in therapeutic preparations. J Immunol Meth 1995; 180: 181-91.
115. Doellgast GJ, Beard GA, Bottoms JD, Cheng T, Roh BH, Roman MG, et al. Enzyme-linked immunosorbent assay and enzyme-linked coagulation assay for detection of Clostridium botulinum neurotoxins A, B, and E and solution-phase complexes with dual-label antibodies. J Clin Microbiol 1994; 32: 105-11.
116. Fach P, Perrelle S, Dilasser F, Grout J, Dargaignaratz C, Botella L, et al. Detection by PCR-enzyme-linked immunosorbent assay of Clostridium botulinum in fish and environmental samples from a coastal area in northern France. Appl Environ Microbiol 2002; 68: 5870-6.
117. Hallis B, James BAF, Shone CC. Development of novel assays for botulinum type A and B neurotoxins based on their endopeptidase activities. J Clin Microbiol 1996; 34: 1934-8.
118. Schmidt JJ, Stafford RG. Fluorigenic substrates for the protease activities of botulinum neurotoxins, serotypes A, B, and F. Appl Environ Microbiol 2003; 69: 297-303.
119. Ferreira JL, Handy MK, McCay SG, Baumstark BR. An improved assay for identification of type A Clostridium botulinum using the polymerase chain reaction. J Rapid Methods Automat Microbiol 1992; 1: 293-9.
120. Campbell KD, Collins MD, East AK. Gene probes for identification of the botulinum neurotoxin gene and specific identification of neurotoxin types B, E and F. J Clin Microbiol 1993; 31: 2255-62.
121. Szabo EA, Pemberton JM, Desmarchelier PM. Detection of genes encoding botulinum neurotoxins types A to E by polymerase chain reaction. Appl Environ Microbiol 1993; 59: 3011-20.
122. Szabo EA, Pemberton JM, Gibson AM, Eyles MJ, Desmarchelier PM. Polymerase chain reaction for detection of Clostridium botulinum type A, B, and E in Food, soil, and infant feces. J Appl Bacteriol 1994; 76: 539-45.
123. Fach P, Hauser D, Guillou JP, Popoff MR. Polymerase chain reaction for the rapid identification of Clostridium botulinum type A strains and detection in food samples. J Appl Bacteriol 1993; 75: 234-9.
124. Hielm S, Hyytia E, Ridell J, Korkeala H. Detection of Clostridium botulinum in fish and environmental samples using polymerase chain reaction. Int J Food Microbiol 1996; 31: 357-65.
125. Aranda E, Rodriguez MM, Asensio MA, Cordoba JJ. Detection of Clostridium botulinum types A, B, E and F in foods by PCR and DNA probe. Lett Appl Microbiol 1997; 25: 186-90.
126. Lindstrom M, Keto R, Markkula A, Nevas M, Hielm S, Korkeala H. Multiplex PCR assay for detection and identification of Clostridium botulinum type A, B, E, and F in food and fecal material. Appl Environ Microbiol 2001; 67: 5694-9.
127. Lin WJ, Johnson EA. Genome analysis of Clostridium botulinum type A by pulsed-field gel electrophoresis. Appl Environ Microbiol 1995; 61: 4441-7.
128. Hielm S, Bjorkroth J, Hyytia E, Korkeala H. Genomic analysis of Clostridium botulinum group II by pulsed-field gel electrophoresis. Appl Environ Microbiol 1998; 64: 703-8.
129. Hielm S, Bjorkroth J, Hyytia, E, Korkeala H. Ribotyping as an identification tool for Clostridium botulinum species causing human botulism. Int J Food Microbiol 1999; 47: 121-31.
130. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, et al. Botulinum toxin as a biological weapon: Medical and public health management. JAMA 2001; 285: 1059-70.
131. Siegel LS. Human response to botulinum pentavalent (ABCDE) toxoid determined by a neutralization test and by an enzyme linked immunosorbent assay. J Clin Microbiol 1988; 25: 2351-6.
132. Pittman PR, Hack D, Mangiafico J, Gibbs P, McKee KT Jr., Friedlander AM, et al. Antibody response to a delayed booster dose of anthrax vaccine and botulinum toxoid. Vaccine 2002; 20: 2107-15.
133. Byrne MP, Smith LA. Development of vaccine for prevention of botulism. Biochimie 2000; 82: 955-66.
134. Atassi MZ, Oshima M. Structure, activity and immune (T & B cell) recognition of botulinum neurotoxin. Crit Rev Immunol 1999; 19: 219-60.
135. Lee JS, Pushko P, Parker MD, Dertzbaugh MT, Smith LA, Smith JF. Candidate vaccine against botulinum neurotoxin serotype A derived from a Venezuelan equine encephalitis virus vector system. Infect Immun 2001; 69: 5709-15.
136. Byrne MP, Smith TJ, Montegomery VA, Smith LA. Purification, potency and efficacy of botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate. Infect Immun 1998; 66: 4817-22.
137. Bennett AM, Perkins SD, Holley JL. DNA vaccination protects against botulinum neurotoxin type F. Vaccine 2003; 21: 3110-7.
138. Zeng M, Xu Q, Elias M, Pichichero ME, Simpson LL, Smith LA. Protective immunity against botulism provided by a single dose vaccination with an adenovirus-vectored vaccine. Vaccine 2007; 25: 7540-8.
139. Xu Q, Pichichero ME, Simpson LL, Elias M, Smith LA, Zeng M. An adenoviral vector-based mucosal vaccine is effective in protection against botulism. Gene Ther 2009; 16: 367-75.
140. Tackett CO, Shandera WX, Mann JM, Hargrett, NT, Blake PA. Equine antitoxin use and other factors that predict outcome in type A foodborne botulism. Am J Med 1984; 76: 794-8.
141. Francisco AM, Arnon SS. Clinical mimics of infant botulism. Pediatrics 2007; 119: 826-8.
142. Sugiyama H. Clostridium botulinum neurotoxin. Microbiol Rev 1980; 44: 419-48.
143. Black RE, Gunn RA. Hypersensitivity reactions associated with botulinal antitoxin. Am J Med 1980; 69: 567-70.
144. Arnon SS. Creation and development of the public service orphan drug human botulism immune globulin. Pediatrics 2007; 119: 785-9.
145. Jing Z, Miao WY, Ding FH, Meng JY, Ye HJ, Jia GR, et al. The effect of toosendanin on monkey botulism. J Tradit Chin Med 1985; 5: 29-30.
146. Shi YL, Wang ZF. Cure of experimental botulism and antibotulismic effect of toosendanin. Acta Pharmacol Sin 2004; 25: 839-48.
147. Shi YL, Li MF. Biological effects of toosendanin, a triterpenoid extracted from Chinese traditional medicine. Prog Neurobiol 2007; 82: 1-10.
148. Fischer A, Nakai Y, Eubanks LM, Clancy CM, Tepp WH, Pellett S, et al. Bimodal modulation of the botulinum neurotoxin protein-conducting channel. Proc Natl Acad Sci USA 2009; 106: 1330-5.
149. Boldt GE, Kennedy JP, Janda KD. Identification of a potent botulinum neurotoxin a protease inhibitor using in situ lead identification chemistry. Org Lett 2006; 8: 1729-32.
150. Burnett JC, Ruthel G, Stegmann CM, Panchal RG, Nguyen TL, Hermone AR, et al. Inhibition of metalloprotease botulinum serotype A from a pseudo-peptide binding mode to a small molecule that is active in primary neurons. J Biol Chem 2007; 282: 5004-14.
151. Kumaran D, Rawat R, Ludivico ML, Ahmed SA, Swaminathan S. Structure and substrate based inhibitor design for Clostridium botulinum neurotoxin serotype A. J Biol Chem 2008; 283: 18883-91.
152. Silvaggi NR, Wilson D, Tzipori S, Allen KN. Catalytic features of the botulinum neurotoxin A light chain revealed by high resolution structure of an inhibitory peptide complex. Biochemistry 2008; 47: 5736-45.
153. Cai S, Singh BR. Strategies to design inhibitors of Clostridium botulinum neurotoxins. Infectious Disorders - Drug Targets 2007; 7: 47-57.
154. Tok JB, Fischer NO. Single microbead SELEX for efficient ssDNA aptamer generation against botulinum neurotoxin. Chem Commun 2008; 28: 1883-5.
155. Zhang P. Ray R, Singh BR, Li D, Adler M, Ray P. An efficient drug delivery vehicle for botulism countermeasure. BMC Pharmacol 2009; 9: 12.
156. Scott AB. Botulinum injection into extraocular muscles as an alternative to strabismus surgery. Opthalmology 1980; 87: 1044-9.
157. Scott AB. Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Opthalmol Soc 1981; 79: 734-70.
158. Lew MF, Adornato BT, Duane DD, Dykstra DD, Factor SA, Massey JM, et al. Botulinum toxin type B: A double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 1997; 49: 701-7.
159. Mezaki T, Kaji R, Kohara N, Fujii H, Katayama M, Shimizu T, et al. Comparison of therapeutic efficacies of type A and F botulinum toxins for blepharospasm: A double-blind, controlled study. Neurology 1995; 45: 506-8.
160. Maselli RA, Burnett ME, Tonsgard JH. In vitro microelectrode study of neuromuscular transmission in a case of botulism. Muscle Nerve 1992;15:273-6.
161. Ranoux D, Gury C, Fondarai J, Mas JL, Zuber M. Respective potencies of Botox® and Dysport®: A double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 2002; 72: 459-62.
162. Sampaio C, Costa J, Ferreira JJ. Clinical comparability of marketed formulations of botulinum toxin. Mov Disord 2004; 19: S129-36.
163. Dressler D, Benecke R. Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil 2007; 29: 1761-8.
164. Jost WH, Blumel J, Grafe S. Botulinum neurotoxin type A free of complexing proteins (Xeomin) in focal dystonia. Drugs 2007; 67: 669-83.
165. Jankovic J. Botulinum toxin therapy for cervical dystonia. Neurotox Res 2006; 9: 145-8.
166. Simpson DM, Gracies JM, Graham HK, Miyasaki JM, Naumann M, Russman B, et al. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review). Neurology 2008; 70: 1691-8.
167. Frei K, Truong DD, Dressler D. Botulinum toxin therapy of hemifacial spasm: comparing different therapeutic preparations. Eur J Neurol 2006; 13: 30-5.
168. Naumann M, Jost W. Botulinum toxin treatment of secretory disorders. Mov Disord 2004; 19: S137-41.
169. Brin MF, Lyons KE, Doucette J, Adler CH, Caviness JN, Comella CL, et al. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology 2001; 56: 1523-8.
170. Lang AM. Botulinum toxin type A therapy in chronic pain disorders. Arch Phys Med Rehabil 2003; 84: S69-73.
171. Schurch B, Schmid DM, Knapp PA. An update on the treatment of detrusor-sphincter dyssynergia with botulinum toxin type A. Eur J Neurol 2007; 6: S83-9.
172. Dutton JJ, Fowler AM. Botulinum toxin in ophthalmology. Surv Ophthalmol 2007; 52: 13-31.
173. Flynn TC. Update on botulinum toxin. Semin Cutan Med Surg 2006; 25: 115-21.
174. Madalinski M, Chodorowski Z. Why the most potent toxin may heal anal fissure. Adv Ther 2006; 23: 627-34.
175. Ghazizadeh S, Nikzad M. Botulinum toxin in the treatment of refractory vaginismus. Obstet Gynecol 2004; 104: 922-5.
176. Thwaini A, Shergill I, Radhakrishnan S, Chinegwundoh F, Thwaini H. Botox in urology. J Int Urogynecol 2006; 17: 536-40.
177. Song PC, Schwartz J, Blitzer A. The emerging role of botulinum toxin in the treatment of temporomandibular disorders. Oral Dis 2007; 13: 253-60.
178. Jankovic J, Brin MF. Botulinum toxin: Historical perspective and potential new indications. Muscle Nerve 1997; 20: S129-45.
179. Blitzer A, Binder WJ, Aviv JE, Keen MS, Brin MF. The management of hyperfunctional facial lines with botulinum toxin. A collaborative study of 210 injection sites in 162 patients. Arch Otolaryngol 1997; 123: 389-92.
180. Anderson ER Jr. Proper dose, preparation, and storage of botulinum neurotoxin serotype A. Am J Health Syst Pharm 2004; 61 (22 Suppl 6): S24-29.
181. Hexsel D, Dal'Forno T, Hexsel C, Do Prado DZ, Lima MM. A randomized pilot study comparing the action halos of two commercial preparations of botulinum toxin type A. Dermatol Surg 2008; 34: 52-9.
182. Singh BR, Thirunavukkarasu N, Ghosal K, Ravichandran E, Kukreja R, Cai S, et al. Clostridial neurotoxins as a drug delivery vehicle targeting nervous system. Biochimie 2010; 92: 12532-9.
183. Chaddock JA, Purkiss JR, Duggan MJ, Quinn CP, Shone CC, Foster KA. A conjugate composed of nerve growth factor coupled to a non-toxic derivative of Clostridium botulinum neurotoxin type A can inhibit neurotransmitter release in vitro. Growth Fact 2000; 18: 147-55.
184. Simpson LL. Identification of the characteristics that underlie botulinum toxin potency: Implications for designing novel drugs. Biochimie 2000; 82: 943-53.